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on quality of sleep, and one in five (22%) reported that an event highly impacted their 
social life. Hypoglycaemic events did not severely effect paid work (n= 16/15), with 
19%/7% (N/D) of respondents reporting arriving at work late or leaving early, and 
13%/7% (N/D) missing ≥ 1 full working day. ConClusions: Nocturnal and daytime 
non-severe hypoglycaemic events have an impact upon patients’ health-related 
quality of life and diabetes management in Colombia.
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objeCtives: While bariatric surgery is being increasingly employed as a cost-
effective option for treatment of obesity, it has not yet realized its full potential. 
Patient participation in the full treatment cycle is key to adoption and outcomes. 
To that end, the objectives of this study were three-fold: 1) Determine how 
patients are expected to share the burden of bariatric surgery treatment efficacy, 
2) Characterize factors that influence patient willingness to adopt and pay, and 3) 
Identify approaches to improve patient outcomes. Methods: Global clinical guide-
lines and HTAs published from 2008-2013 were analyzed. These results were collated 
with a survey of 2,784 patients across 12 countries, representing major markets in 
the Americas, Europe, Middle East, and Asia. Surveyed patients were in 26 – 50 age-
groups and with BMI in the 34.3 – 43.4 kg/m2 range. It evaluated patients’ perception 
of barriers in terms of cost and safety, and motivators to adopt surgical procedures 
for treatment of obesity. Results: Clinical guidelines and HTAs recommended 
that pre-treatment patients comply with weight-loss regimens, and post-treatment 
adhere to severe dietary restrictions, life-style changes, and life-long follow-up. 
The survey indicated that while patient age, income level, and physicians’ opinion 
were strong indicators of patients’ likelihood of considering surgery, BMI was not. 
Importantly, three significant barriers to adoption were identified: a) lack of under-
standing of safety and efficacy, b) the perceived out-of-pocket cost of treatment, and 
c) the extent of sustainable life style changes expected of patients. ConClusions: 
Although bariatric surgery is considered potentially clinically- and cost-effective, 
patient willingness to undertake surgery indicates a chasm between perception 
and reality. To aid in bridging that gap, findings suggested that three key issues 
must be addressed: a) improve patient education and physician engagement, b) 
expand the evidence base to demonstrate long-term clinical benefits of surgery, 
including metabolically-related risk factors, and c) demonstrate economic benefits 
to price-sensitive patients.
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objeCtives: To evaluate the impact of an employer-based copayment waiver for 
diabetes care on medication adherence, diabetes care and spending among enrollees 
with diabetes and within subgroups of patients who had low use, moderate use, 
and adherent use of diabetes medications prior to start of the benefit. Methods: 
Enrollees in eligible health plans with diabetes were automatically enrolled in a 
copayment waiver ($0 copay) benefit beginning January 2011 for diabetes, cardio-
vascular, and lipid lowering medications, screenings, diabetes supplies, and diabe-
tes related office visits. The study included 444 enrollees with diabetes who were 
propensity score matched to a comparison group of patients with diabetes within 
nine similar firms without these benefits (N= 444 comparison). An enrollee-calendar 
quarter panel data set was constructed from January 2009-June 2012. Impact was 
measured as the change in outcomes post-enrollment in the copayment waiver 
group relative to the change in the comparison group (difference-in-differences). 
Percent of Days Covered (PDC) with diabetes medications prior to 2011 was used to 
classify patients: low adherence (PDC< 20%, N= 127 treatment, N= 127 comparison), 
moderate adherence (20%≤ PDC< 80%, N= 115 treatment, N= 115 comparison), and 
adherent (PDC≥ 80%, N= 202 treatment, N= 202 comparison). Results: In the full 
sample, PDC for oral diabetes medications increased 8.7% points to 54.2% (13.3% 
increase, P< 0.01), the number of outpatient office visits for diabetes increased 
10.8% (P= 0.03) and prescription fills of diabetes supplies increased 29.1% (P< 0.01). 
Among enrollees with low prior adherence, PDC increased from 10.5% to 20.9% 
(95% increase, P< 0.01). In the full sample, total spending (medical plus prescription 
drug) did not change (P= 0.76). ConClusions: Results through the first eighteen 
months show that waiving copayments for patients with diabetes can improve 
adherence to diabetes medication, office visits and supplies with a minimal impact 
on spending. Large increases in adherence occurred for patients with the low levels 
of pre-program adherence.
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objeCtives: No consensus exists among the ADA and the AACE guidelines 
regarding therapy intensification for patients with type 2 diabetes mellitus (T2DM) 
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objeCtives: To study the effect of nocturnal and daytime non-severe hypoglycae-
mic events on people with diabetes in Singapore. Methods: People with diabe-
tes from five countries, including Singapore, who had experienced a non-severe 
hypoglycaemic event in the 4 weeks prior to the survey were eligible. Both surveys 
were conducted face to face; all information, including hypoglycaemic events, was 
self-reported. Results: In the Singaporean cohort, 76 people responded (50 for 
the nocturnal survey [N]; 51 for the daytime survey [D]). Mean age was 54 years/56 
years (N/D), mean weight was 63.2 kg/68.3 kg (N/D), 48%/49% (N/D) were male, 
and 70%/80% (N/D) had type 2 diabetes. Among respondents with type 2 diabe-
tes, 11%/10% (N/D) received insulin and 100%/100% (N/D) received oral medication. 
Almost half of respondents had diabetes-related complications (46%/49% [N/D]), 
and 16%/18% (N/D) experienced hypoglycaemia at least once/week. When asked 
about hypoglycaemia awareness, 14%/14% (N/D) reported only noticing they were 
hypoglycaemic during routine blood glucose checks, while 8%/16% (N/D) were gener-
ally unaware of an event. After a hypoglycaemic event, 12%/20% contacted a health 
care professional and, in the following week, used on average 1.1/2.1 (N/D) extra 
blood glucose strips. Following a nocturnal event, mean time to return to sleep was 
63 minutes; 24% reported difficulty returning to sleep after the event, almost two 
thirds (62%) felt tired and/or fatigued the next day, and 22% reported high level of 
fear of a future event. In the daytime survey, the most common measures taken 
in order to avoid hypoglycaemia were defensive snacking and avoiding exercise. 
Respondents reported spending most time worrying about feeling lightheaded/
dizzy, having an event while alone, and passing out in public. ConClusions: In 
Singapore, hypoglycaemic events impact health care utilisation and daily routines 
for people with diabetes. Treatment strategies to decrease hypoglycaemia could 
offer substantial benefits to people with diabetes.
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objeCtives: To study the effect of nocturnal and daytime non-severe hypoglycae-
mic events on the utilisation of health care services and patient quality of life in 
Mexico. Methods: People with diabetes from six different countries who had expe-
rienced a self-reported non-severe hypoglycaemic event in the past 4 weeks were 
eligible to take part in a nocturnal (N) and/or daytime (D) hypoglycaemia survey. In 
the Mexican cohort, 77 people responded (50 for the nocturnal survey; 50 for the day-
time survey). The surveys were conducted either face to face or online. Results: In 
the Mexican subgroup, 82%/80% (N/D) of respondents had type 2 diabetes, 38%/42% 
(N/D) were male, mean age was 52 years/53 years (N/D), and mean weight was 74.4 
kg/75.6 kg (N/D). Respondents received treatment with insulin (32%/38% [N/D]), oral 
medication (95%/95% [N/D]) and/or diet and exercise (49%/58% [N/D]), and 70%/76% 
considered themselves in good health. Non-severe hypoglycaemic episodes were 
experienced at least once weekly by 34%/44% (N/D) and at least once a month 
by 76%/68% (N/D) of respondents. After a hypoglycaemic event, 41%/16% (N/D) of 
respondents decreased their insulin dose, 50%/58% contacted a health care profes-
sional, and, in the following week, used on average 2/5 (N/D) extra blood glucose 
strips. Almost half of respondents reported a high level of fear of hypoglycaemic 
events (46%/46% [N/D]). Following a nocturnal hypoglycaemic event, mean time to 
return to sleep was 89 minutes, 11% did not go back to sleep at all, and 38% reported 
the nocturnal event had a high impact on their quality of sleep. Of respondents who 
worked for pay (n= 23/21), 30%/67% (N/D) went to work late or left early, and 13%/24% 
(N/D) missed ≥ 1 full working day. ConClusions: In Mexico, nocturnal and daytime 
non-severe hypoglycaemic events severely impact quality of life, quality of sleep 
and productivity in people with diabetes.
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objeCtives: To study the effect of nocturnal and daytime non-severe hypoglycae-
mic events on the utilisation of health care services and health-related quality of life 
in people with diabetes in Colombia. Methods: People with diabetes from five dif-
ferent countries who had experienced a non-severe hypoglycaemic event in the past 
4 weeks were asked to take part in a nocturnal (N) and/or daytime (D) hypoglycaemia 
survey. In the Colombian subgroup, 83 people responded (50 respondents for the 
nocturnal survey; 50 for the daytime survey). Both surveys were conducted face-to-
face. All information, including hypoglycaemic events, was self-reported. Results: 
In the Colombian cohort, respondents’ mean age was 58 years/54 years (N/D), mean 
weight was 64.3 kg/65.5 kg (N/D), 36%/38% (N/D) were male, 76%/76% (N/D) had type 
2 diabetes, and all received treatment with insulin (100%/100% [N/D]). Although 
78%/82% (N/D) of respondents considered themselves in good health, almost half 
had diabetes-related complications (48%/54% [N/D]). Non-severe hypoglycaemic 
episodes were experienced at least once weekly by 16%/20% (N/D) and at least once 
a month by 70%/70% (N/D). After a hypoglycaemic event, 0%/24% (N/D) decreased 
their insulin dose, 32%/40% contacted a health care professional, and, in the follow-
ing week, they used on average 5/6 (N/D) extra blood glucose strips. The majority 
of respondents reported a high level of fear of nocturnal hypoglycaemic events 
(60%/36% [N/D]). One third (32%) reported that a nocturnal event had a high impact 
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respectively, which shows that usage of drugs associated with higher SHE risks var-
ies between countries. E.g. in type 1 DM 42.65% patients in Hungary use basal-bolus 
with human basal (related to 1.1 events/person-year), while only 8% in Croatia. In 
type 2 DM 9.37% patients in Hungary use basal-bolus regimen with basal human 
insulin (0.6 events /person-year), and only 0.5% in Croatia. ConClusions: Rates 
of SHEs differ for T1, T2 and drug regimens. Various treatment schemes prevail in 
analysed countries, which result in different total (estimated) risks. However, other 
factors may impact the actual SHE incidence and motivate treatment selection in 
the first place. Therefore the results should not be used to draw conclusions regard-
ing the overall quality of DM patients care.
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objeCtives: The Syreon model was developed to predict the long term effects 
of screening, treatment and control of type 2 diabetes. After a successful internal 
and external validation the model is capable of analyzing the consequences of 
different macro-level policy interventions. The aim of this analysis was to assess 
the cost-effectiveness of the introduction of a risk stratified population screening 
compared to no screening in Hungary. Methods: The screening program consists 
of two major elements. The first covers the use of the internationally validated 
FINDRISC questionnaire to identify people at high risk of diabetes. Answers to the 
questionnaire are simulated based on individual characteristics. The second part of 
the module refers the high risk (FINDRISC score > = 12) population to oral glucose 
tolerance test. After completion of the screening program, patients enter the disease 
progression and treatment module. The screening process can be repeated over 
defined periods, e.g. every 3 years. Results: Introduction of 3 yearly risk stratified 
screening for 50-60 age groups with not known diabetes was estimated to result 
in an incremental cost-effectiveness ratio of 32 000 PPP $/QALY. The results were 
sensitive to the starting age of the target group, the frequency and the stopping age 
of the organized screening. ConClusions: Risk stratified screening program was 
predicted to be cost-effective compared with no screening in Hungary in certain 
age-groups. Early diagnosis of type 2 diabetes contributes to earlier treatment that 
results in better health and less complications.
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objeCtives: The total estimated cost of diagnosed diabetes in the United States 
(US) in 2012 was $245 billion. Although the cost of diabetic supplies is reported to 
be less than 2% of total expenditures, the fractional cost contribution of the most 
common insulin delivery devices, critical to disease management, remain unknown. 
The objective of this study is to understand the cost distribution among pharmacy 
benefit diabetic supplies and quantify the impact of manual insulin delivery devices 
on the overall cost of diabetes in the US. Methods: A cross-sectional analysis 
of the 2010 Medical Expenditure Panel Survey (MEPS) database was conducted. 
Diabetic supplies were identified from the linked prescription file and categorized 
through identification of National Drug Codes, prescription names and prescription 
form variables. Non-pharmacy benefits including insulin pumps were excluded. 
Expenditures were calculated as the sum source payments and reported in 2012 
dollars. Weighted mean expenditures per diabetic were calculated using SAS 9.2 
SURVEYMEANS procedure. A prevalence-based approach was used to extrapolate 
to the 2012 U.S. diabetic population. Results: 2,440 diabetics were included. The 
sample was 55% female and 12% uninsured with a mean age of 58 (±16.48). The 
estimated total diabetic supply expenditures in the U.S. in 2012 were $3,598,491,566. 
Test strips were the largest contributors to this category (74.7%, $2,689,696,646) fol-
lowed by insulin pens (7.1%), pen needles (6.8%) and syringes (5.1%). Insulin delivery 
devices (limited to insulin pen needles and insulin syringes) contribute 0.24% of 
U.S. direct medical expenditures and 0.17% of the total U.S. expenditures on diabe-
tes. ConClusions: These results highlight the fractional contribution that diabetic 
supplies, and more specifically manual insulin delivery devices, contribute to the 
overall costs attributed to diabetes in the U.S. Further research should consider 
the positive cost implications that such devices may have on diabetes outcomes.
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objeCtives: Our objectives were to understand patient experience with and uti-
lization of manufacturer-sponsored patient support programs for type 2 diabetes 
(T2DM) injectable therapy. Methods: Data for these analyses were drawn from 
a larger cross-sectional survey evaluating treatment adherence and persistence 
among T2DM patients in the US age ≥ 18 who had been prescribed an injectable 
medication. Patients were recruited from a general-population on-line panel, and 
recruitment was stratified by medication and discontinuation status. Analyses are 
limited to the 3 medications for which ≥ 25 respondents reported using the cor-
responding patient support program: exenatide once weekly, liraglutide, insulin 
glargine. Proportions were calculated using a drop-out weighting method. Results: 
Bydureon Steady Support (BSS) was utilized by 26% of exenatide once weekly 
patients (51/200), 14% of liraglutide patients (83/598) utilized Victoza Care (VC), 
and 10% of insulin glargine patients 48/488) utilized Lantus Connection (LC). Those 
inadequately controlled by metformin (MET) monotherapy. This study aimed to 
understand the treatment regimens of Medicare Advantage with Prescription Drug 
coverage (MAPD) patients in a large national health plan who newly initiate MET 
monotherapy, and assess factors associated with changes in therapy in the 12 
months after MET initiation. Methods: This was a retrospective cohort analysis 
of medical and pharmacy claims of 17,527 MAPD members aged 18-89, with ≥ 1 
medical claim containing a primary diagnosis or ≥ 2 medical claims containing a 
secondary diagnosis of T2DM, and with an initial prescription fill for MET between 
1/1/2008 and 9/30/2011. Demographic and clinical characteristics were analyzed 
using descriptive statistics; factors associated with treatment changes were exam-
ined using Cox proportional hazard regression models. Results: 59% of MAPD 
patients (mean age 69.6 years) remained on MET monotherapy with no changes. 
Discontinuation was the most common treatment change (33%), followed by addi-
tion (5%), and switching (2%). Of patients who discontinued treatment (median 
time to discontinuation= 90 days), 61% did not re-initiate any diabetic treatment 
during the 12 month follow-up period. Among those who added or switched to 
other antidiabetics, sulfonylureas were the most commonly-added or switched-
to drugs. Discontinuation was predicted by being female (hazard ratio [HR] 1.06, 
[1.003;1.12]95%CI), having more comorbidities (HR 1.00, [1.01;1.04]95%CI) or a diag-
nosis of depression (HR 1.18, [1.08;1.27]95%CI) in the 12 months before initiating 
MET; in MAPD aged ≥ 65 (n= 14,389), discontinuation was predicted by a higher 
baseline daily average consumption (DACON) of MET (HR 1.00, [1.0002;1.0006]95%CI).  
ConClusions: Discontinuation of MET was the most common treatment change 
in this population. Being female, having a higher baseline DACON of MET, more 
comorbidities or a diagnosis of depression were all predictors of discontinuation.
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objeCtives: Early metabolic abnormalities that precede diabetes (impaired fast-
ing glucose and impaired glucose tolerance) are associated with increased mortal-
ity. Our study aimed to assess the relationship between random glucose levels 
and development of all-cause mortality, specifically considering the differences 
between normal, high-normal glucose, pre-diabetes and diabetes. Methods: A 
retrospective cohort study using a limited dataset from the Framingham Heart 
Study was employed. Baseline-period was in 1956, each patient was followed 
24 years. Random glucose was grouped into normal, high-normal, pre-diabetes, 
and diabetes. Ages, gender, body mass index, and blood pressure were examined. 
Outcome measure was all-cause mortality. Bivariate and multivariate cox propor-
tional hazards regression models controlling for demographics and risk factors 
were performed to compare the risk of death between different random glucose 
levels. Results: The study cohort consisted of 3,270 survey patients with a mean 
age 50(±8.68), of which 1,825(55.8%) were female. During the follow-up period, 1,178 
patients deceased. The average follow-up time was 20 years; while average sur-
vival time for patients who deceased was 14 years. Compared to normal random 
glucose, high-normal (Hazard Ratio[HR]:1.486; Confidence Interval[CI]:1.24 –1.77), 
pre-diabetes (HR:3.328; CI:2.237–4.951) and diabetes (HR:5.314; CI:3.754–7.523) were 
significantly associated with increased risk of all-cause death in the bivariate Cox 
regression model. In adjusted model, high-normal glucose level (HR:1.216; CI:1.019–
1.45), pre-diabetes(HR:2.458; CI:1.647–3.667), and diabetes (HR:3.164; CI:2.214– 4.521) 
were significantly associated with increased risk of death compared to normal 
glucose group; age and hypertensive systolic blood pressure were associated with 
increased risk of all-cause death; while female gender was significantly associated 
with decreased risk of death. ConClusions: Random glucose alone can predict 
risk and even high-normal levels are associated with increased mortality. Our find-
ings are of value especially when considering cost-effective strategies in screening 
underserved populations throughout the globe, where medical resources are scarce 
and fasting glucose levels are difficult to obtain.
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objeCtives: Severe (requiring another person’s assistance) hypoglycaemic events 
(SHEs) matter from clinical and economic perspective. Various risk factors are men-
tioned in the literature (drugs used, patients’ adherence, diet, exercise). We aimed 
to compare diabetes mellitus (DM) treatment patterns in Croatia, Czech Republic, 
Hungary, Poland and Slovenia with respect to the resulting risk of SHE. Methods: 
We performed a systematic review to assess the drug related annual SHE rates for 
various treatments (shown in past ISPOR meetings) defined depending on using oral 
antidiabetic medications, sulfonylureas, insulins–split into basal-bolus/biphasic, 
and analogues/human. Epidemiological data were based on national registries, pre-
scription databases, published studies, questionnaire surveys. Market shares were 
based on IMS data (Croatia, Czech Republic, Poland), National Health Insurance Fund 
(Hungary), prescription database (Slovenia). Results: Using SHE rates estimates 
for individual treatment schemes and epidemiological and market data we arrived 
at the following estimates of the annual total number of SHEs: Croatia – 16,975, 
Czech Republic – 80,884, Hungary – 62,282, Poland – 217,711, and Slovenia – 9,291. 
When expressed per one DM patient we got annually: 0.078, 0.117, 0.143, 0.120, 0.096, 
